Tag - ACRS

Developments

Aclaris doses first patient in Phase 2a atopic dermatitis trial

Aclaris Therapeutics (NASDAQ:ACRS) dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate-to-severe atopic dermatitis ATI-1777 is a topical Janus kinase (JAK) 1/3 inhibitor...

October 20, 2020

Markets

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

SVB Leerink upgraded Aclaris Therapeutics (NASDAQ:ACRS) to “outperform” from “market perform” and raised its price target to $3.50 from $1.50, citing a new focus at the company. The stock closed at $1.41 on Oct. 21...

October 22, 2019

Tag - ACRS

Aclaris doses first patient in Phase 2a atopic dermatitis trial

SVB Leerink ups Aclaris Therapeutics to OP; PT to $3.50 from $1.50

General

More